Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	At Market Equity Offering Program	Common Stock	Common Stock At Market Equity Offering Program	Additional Paid-in Capital	Additional Paid-in Capital At Market Equity Offering Program	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2022			105,144,864
Balance at beginning of period at Dec. 31, 2022	$ 92,057		$ 11		$ 746,889		$ (152)	$ (654,691)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				3,535,093
Issuance of common stock from at-the-market transactions, net of issuance costs		$ 21,795				$ 21,795
Exercise of stock options (in shares)			8,826
Exercise of stock options	34				34
Vesting of restricted stock units and other stock awards (in shares)			372,291
Stock-based compensation expense	6,407				6,407
Other comprehensive gain (loss)	164						164
Net loss	(56,163)							(56,163)
Balance at end of period (in shares) at Mar. 31, 2023			109,061,074
Balance at end of period at Mar. 31, 2023	64,294		$ 11		775,125		12	(710,854)
Balance at beginning of period (in shares) at Dec. 31, 2022			105,144,864
Balance at beginning of period at Dec. 31, 2022	92,057		$ 11		746,889		(152)	(654,691)
Increase (Decrease) in Stockholders' Equity
Net loss	(110,470)
Balance at end of period (in shares) at Jun. 30, 2023			120,459,232
Balance at end of period at Jun. 30, 2023	89,800		$ 12		854,998		(49)	(765,161)
Balance at beginning of period (in shares) at Mar. 31, 2023			109,061,074
Balance at beginning of period at Mar. 31, 2023	64,294		$ 11		775,125		12	(710,854)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				10,929,438
Issuance of common stock from at-the-market transactions, net of issuance costs		71,875		$ 1		71,874
Exercise of stock options (in shares)			88,770
Exercise of stock options	393				393
Vesting of restricted stock units and other stock awards (in shares)			88,690
Purchase of common stock under ESPP (in shares)			291,260
Purchase of common stock under ESPP	963				963
Stock-based compensation expense	6,643				6,643
Other comprehensive gain (loss)	(61)						(61)
Net loss	(54,307)							(54,307)
Balance at end of period (in shares) at Jun. 30, 2023			120,459,232
Balance at end of period at Jun. 30, 2023	$ 89,800		$ 12		854,998		(49)	(765,161)
Balance at beginning of period (in shares) at Dec. 31, 2023	120,711,745		120,711,745
Balance at beginning of period at Dec. 31, 2023	$ 36,904		$ 12		863,242		11	(826,361)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				1,041,201
Issuance of common stock from at-the-market transactions, net of issuance costs		$ 5,780				$ 5,780
Exercise of stock options (in shares)			12,117
Exercise of stock options	48				48
Vesting of restricted stock units and other stock awards (in shares)			594,067
Stock-based compensation expense	4,660				4,660
Other comprehensive gain (loss)	(101)						(101)
Net loss	(19,306)							(19,306)
Balance at end of period (in shares) at Mar. 31, 2024			122,359,130
Balance at end of period at Mar. 31, 2024	$ 27,985		$ 12		873,730		(90)	(845,667)
Balance at beginning of period (in shares) at Dec. 31, 2023	120,711,745		120,711,745
Balance at beginning of period at Dec. 31, 2023	$ 36,904		$ 12		863,242		11	(826,361)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)	14,223
Net loss	$ (43,574)
Balance at end of period (in shares) at Jun. 30, 2024	122,675,051		122,675,051
Balance at end of period at Jun. 30, 2024	$ 8,427		$ 12		878,421		(71)	(869,935)
Balance at beginning of period (in shares) at Mar. 31, 2024			122,359,130
Balance at beginning of period at Mar. 31, 2024	27,985		$ 12		873,730		(90)	(845,667)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)			2,106
Exercise of stock options	8				8
Vesting of restricted stock units and other stock awards (in shares)			160,086
Purchase of common stock under ESPP (in shares)			153,729
Purchase of common stock under ESPP	258				258
Stock-based compensation expense	4,425				4,425
Other comprehensive gain (loss)	19						19
Net loss	$ (24,268)							(24,268)
Balance at end of period (in shares) at Jun. 30, 2024	122,675,051		122,675,051
Balance at end of period at Jun. 30, 2024	$ 8,427		$ 12		$ 878,421		$ (71)	$ (869,935)